vs
Side-by-side financial comparison of Hologic (HOLX) and SEALED AIR CORP (SEE). Click either name above to swap in a different company.
SEALED AIR CORP is the larger business by last-quarter revenue ($1.4B vs $1.0B, roughly 1.3× Hologic). Hologic runs the higher net margin — 17.1% vs 3.1%, a 13.9% gap on every dollar of revenue. On growth, SEALED AIR CORP posted the faster year-over-year revenue change (2.6% vs 2.5%). SEALED AIR CORP produced more free cash flow last quarter ($257.7M vs $215.2M). Over the past eight quarters, SEALED AIR CORP's revenue compounded faster (2.7% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Sealed Air Corporation is a global provider of innovative packaging and protective solutions. Its core offerings include cushioning materials, food safety and preservation packaging, and sustainable waste-reducing packaging systems, serving retail, e-commerce, food and beverage, and industrial manufacturing markets worldwide.
HOLX vs SEE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $1.4B |
| Net Profit | $179.1M | $43.8M |
| Gross Margin | 56.0% | 28.6% |
| Operating Margin | 22.6% | 11.4% |
| Net Margin | 17.1% | 3.1% |
| Revenue YoY | 2.5% | 2.6% |
| Net Profit YoY | -10.9% | 700.0% |
| EPS (diluted) | $0.79 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $1.4B | ||
| Q3 25 | $1.0B | $1.3B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.0B | $1.3B | ||
| Q4 24 | $1.0B | $1.4B | ||
| Q3 24 | $988.0M | $1.3B | ||
| Q2 24 | $1.0B | $1.3B | ||
| Q1 24 | $1.0B | $1.3B |
| Q4 25 | $179.1M | $43.8M | ||
| Q3 25 | $187.2M | $255.1M | ||
| Q2 25 | $194.9M | $93.1M | ||
| Q1 25 | $-17.4M | $113.5M | ||
| Q4 24 | $201.0M | $-7.3M | ||
| Q3 24 | $178.6M | $91.7M | ||
| Q2 24 | $194.5M | $98.3M | ||
| Q1 24 | $169.9M | $82.0M |
| Q4 25 | 56.0% | 28.6% | ||
| Q3 25 | 55.6% | 29.8% | ||
| Q2 25 | 56.3% | 30.7% | ||
| Q1 25 | 37.5% | 30.9% | ||
| Q4 24 | 56.8% | 30.0% | ||
| Q3 24 | 56.4% | 30.1% | ||
| Q2 24 | 55.4% | 31.2% | ||
| Q1 24 | 53.3% | 30.3% |
| Q4 25 | 22.6% | 11.4% | ||
| Q3 25 | 22.6% | 13.8% | ||
| Q2 25 | 24.9% | 15.0% | ||
| Q1 25 | -0.7% | 14.5% | ||
| Q4 24 | 22.5% | 11.7% | ||
| Q3 24 | 23.3% | 13.9% | ||
| Q2 24 | 24.1% | 15.4% | ||
| Q1 24 | 20.7% | 14.0% |
| Q4 25 | 17.1% | 3.1% | ||
| Q3 25 | 17.8% | 19.0% | ||
| Q2 25 | 19.0% | 7.0% | ||
| Q1 25 | -1.7% | 9.0% | ||
| Q4 24 | 19.7% | -0.5% | ||
| Q3 24 | 18.1% | 6.9% | ||
| Q2 24 | 19.2% | 7.4% | ||
| Q1 24 | 16.7% | 6.2% |
| Q4 25 | $0.79 | $0.30 | ||
| Q3 25 | $0.84 | $1.73 | ||
| Q2 25 | $0.86 | $0.63 | ||
| Q1 25 | $-0.08 | $0.77 | ||
| Q4 24 | $0.87 | $-0.05 | ||
| Q3 24 | $0.75 | $0.63 | ||
| Q2 24 | $0.82 | $0.67 | ||
| Q1 24 | $0.72 | $0.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $344.0M |
| Total DebtLower is stronger | $2.5B | $3.3B |
| Stockholders' EquityBook value | $5.2B | $1.2B |
| Total Assets | $9.2B | $7.0B |
| Debt / EquityLower = less leverage | 0.48× | 2.65× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $344.0M | ||
| Q3 25 | $2.2B | $282.5M | ||
| Q2 25 | $1.9B | $354.4M | ||
| Q1 25 | $1.6B | $335.2M | ||
| Q4 24 | $2.0B | $371.8M | ||
| Q3 24 | $2.3B | $386.0M | ||
| Q2 24 | $2.4B | $388.6M | ||
| Q1 24 | $2.2B | $352.8M |
| Q4 25 | $2.5B | $3.3B | ||
| Q3 25 | $2.5B | $4.0B | ||
| Q2 25 | $2.5B | $4.0B | ||
| Q1 25 | $2.5B | $4.2B | ||
| Q4 24 | $2.5B | $4.2B | ||
| Q3 24 | $2.5B | $4.3B | ||
| Q2 24 | $2.5B | $4.4B | ||
| Q1 24 | $2.6B | $4.5B |
| Q4 25 | $5.2B | $1.2B | ||
| Q3 25 | $5.0B | $1.2B | ||
| Q2 25 | $4.8B | $953.1M | ||
| Q1 25 | $4.6B | $797.9M | ||
| Q4 24 | $4.8B | $624.5M | ||
| Q3 24 | $5.1B | $771.2M | ||
| Q2 24 | $5.0B | $650.1M | ||
| Q1 24 | $4.8B | $598.3M |
| Q4 25 | $9.2B | $7.0B | ||
| Q3 25 | $9.0B | $7.1B | ||
| Q2 25 | $8.8B | $7.2B | ||
| Q1 25 | $8.5B | $7.0B | ||
| Q4 24 | $8.7B | $7.0B | ||
| Q3 24 | $9.2B | $7.3B | ||
| Q2 24 | $8.9B | $7.3B | ||
| Q1 24 | $8.7B | $7.2B |
| Q4 25 | 0.48× | 2.65× | ||
| Q3 25 | 0.50× | 3.34× | ||
| Q2 25 | 0.52× | 4.18× | ||
| Q1 25 | 0.55× | 5.26× | ||
| Q4 24 | 0.53× | 6.72× | ||
| Q3 24 | 0.49× | 5.62× | ||
| Q2 24 | 0.51× | 6.81× | ||
| Q1 24 | 0.53× | 7.49× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $293.6M |
| Free Cash FlowOCF − Capex | $215.2M | $257.7M |
| FCF MarginFCF / Revenue | 20.5% | 18.5% |
| Capex IntensityCapex / Revenue | 1.4% | 2.6% |
| Cash ConversionOCF / Net Profit | 1.28× | 6.70× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $458.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $293.6M | ||
| Q3 25 | $355.1M | $165.9M | ||
| Q2 25 | $343.3M | $136.6M | ||
| Q1 25 | $169.4M | $31.9M | ||
| Q4 24 | $189.3M | $244.2M | ||
| Q3 24 | $367.0M | $170.5M | ||
| Q2 24 | $405.8M | $188.2M | ||
| Q1 24 | $292.4M | $125.1M |
| Q4 25 | $215.2M | $257.7M | ||
| Q3 25 | $341.4M | $119.6M | ||
| Q2 25 | $330.5M | $93.2M | ||
| Q1 25 | $153.9M | $-12.0M | ||
| Q4 24 | $172.5M | $185.1M | ||
| Q3 24 | $350.6M | $115.2M | ||
| Q2 24 | $385.3M | $129.5M | ||
| Q1 24 | $279.6M | $78.0M |
| Q4 25 | 20.5% | 18.5% | ||
| Q3 25 | 32.5% | 8.9% | ||
| Q2 25 | 32.3% | 7.0% | ||
| Q1 25 | 15.3% | -0.9% | ||
| Q4 24 | 16.9% | 13.6% | ||
| Q3 24 | 35.5% | 8.6% | ||
| Q2 24 | 38.1% | 9.7% | ||
| Q1 24 | 27.5% | 5.9% |
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.3% | 3.4% | ||
| Q2 25 | 1.3% | 3.3% | ||
| Q1 25 | 1.5% | 3.5% | ||
| Q4 24 | 1.6% | 4.4% | ||
| Q3 24 | 1.7% | 4.1% | ||
| Q2 24 | 2.0% | 4.4% | ||
| Q1 24 | 1.3% | 3.6% |
| Q4 25 | 1.28× | 6.70× | ||
| Q3 25 | 1.90× | 0.65× | ||
| Q2 25 | 1.76× | 1.47× | ||
| Q1 25 | — | 0.28× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | 1.86× | ||
| Q2 24 | 2.09× | 1.91× | ||
| Q1 24 | 1.72× | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
SEE
| Protective Segment | $1.1B | 78% |
| Other | $292.0M | 21% |
| Pension Plans Defined Benefit | $7.9M | 1% |
